Myfembree denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for myfembree are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Myfembree for Medical Necessity — and How to Build a Winning Appeal

A medical necessity denial for Myfembree (relugolix, estradiol, and norethindrone acetate) means Cigna's reviewer concluded that the clinical documentation submitted did not sufficiently establish that this specific therapy is required for your condition. This is one of the most common — and most frequently overturned — denial types, because it is driven by the completeness and specificity of what was submitted, not by a categorical exclusion. The solution is a thoroughly documented appeal that directly addresses every criterion in Cigna's coverage policy.

## The Federal Appeal Framework

• Internal appeal (Level 1): File a written appeal within Cigna's stated deadline (generally 180 days from the denial notice). Cigna must issue a decision within 30 days for non-urgent pre-service requests; 72 hours for expedited urgent reviews; 60 days for post-service claims.
• Peer-to-peer review: Before or during the appeal, ask your prescriber to request a peer-to-peer call with Cigna's reviewing medical director. This often resolves medical necessity denials without advancing to formal appeal.
• External review (ACA §2719): After a final internal denial, request independent external review — generally within 4 months. The IRO applies generally accepted clinical standards, not just Cigna's internal policy.
• ERISA §503: Employer plan members are entitled to a denial notice with the specific clinical criteria Cigna applied and the specific reasons the submitted documentation failed to satisfy them.

## Documents to Gather

1. Diagnosis and severity documentation: Chart notes, specialist records, and diagnostic workup confirming the diagnosis (endometriosis-associated pain or fibroid-related heavy menstrual bleeding) and documenting clinical severity — impact on function, quality of life, and prior treatment failures. 2. Prior treatment history: A detailed timeline of all prior therapies tried, with start and end dates, doses used, clinical response, and reasons for discontinuation. Refer to the FDA-approved prescribing information for Myfembree to confirm which prior-therapy requirements your history satisfies. 3. Prescriber medical-necessity letter: This is the cornerstone of the appeal. The letter should explain the diagnosis, the inadequacy of prior treatments, why Myfembree is clinically appropriate for this patient, and how the patient's situation meets the criteria described in Cigna's coverage policy. The physician should reference the applicable specialty guideline organization's recommendations generically. 4. Cigna's coverage policy: Obtain a copy of the specific Cigna clinical policy applied to this denial. Map each listed criterion to your documentation. 5. FDA prescribing label: Confirm the approved indication and ensure the prescribed use is within that indication.

## Criteria-Mapping Structure

In the appeal letter body, reproduce each criterion from Cigna's medical policy. Beneath each one, cite the precise chart note, date, and finding that satisfies it. For example:

• Criterion: Diagnosis of [condition]. → [Cite specialist note dated X, confirmed by Y.]
• Criterion: Prior therapy. → [Cite dates, agents, and outcomes from treatment history.]
• Criterion: Clinical severity. → [Cite the chart documentation.]

A point-by-point response is significantly more likely to succeed than a narrative letter that does not directly address the policy criteria.